HOME
HIV and AIDS
Hepatitis B
Hepatitis C
HIV-HCV Coinfection
HIV-HBV Coinfection
HIV and AIDS Articles on:
  FDA-approved Treatments
 
Experimental Treatments
 
Top New Articles
HOME PAGE

Low Tidal Volume Ventilation Is Associated with Reduced Mortality in HIV Patients with Acute Lung Injury

Respiratory failure remains the main indication for intensive care unit (ICU) admission and is still a leading cause of death for HIV-infected individuals despite overall improvements in ICU mortality.

It is unclear whether these improvements are due to combination antiretroviral therapy, low tidal-volume ventilation for acute lung injury, or both.

The aims of the current study, published in the June 5, 2008 online edition of Thorax, were to:

Identify therapies and clinical factors associated with mortality related to acute lung injury among HIV-infected patients with respiratory failure during the period 1996-2004.

Compare mortality in 2002, before and after introduction of low tidal volume-ventilation, a method that supports adequate ventilation and oxygenation in people with acute lung injury, such as may occur due to Pneumocystis pneumonia or other serious lung conditions.

Researchers at the University of California in San Francisco performed a retrospective cohort study of 148 consecutive HIV-infected adults admitted to the ICU at San Francisco General Hospital with acute lung injury requiring mechanical ventilation.

The investigators abstracted demographic and clinical information from medical records, including data on mechanical ventilation, and performed multivariate analysis using logistic regression.

Results

In-hospital mortality was similar before and after introduction of a low tidal-volume ventilation protocol, although the study was not powered to exclude a clinically significant difference (P = 0.51).

Combination antiretroviral therapy was not clearly associated with mortality, except among patients with Pneumocystis pneumonia.

Among patients with acute lung injury, lower tidal volume was associated with decreased mortality after controlling for Pneumocystis pneumonia, serum albumin, severity of illness, gas-exchange impairment, and plateau pressure (P = 0.043).

Based on these findings, the study authors concluded, "Lower tidal volume ventilation was independently associated with reduced mortality in HIV-infected patients with acute lung injury and respiratory failure."

University of California, San Francisco, CA.

6/17/08

Reference

JL Davis, A Morris, RH KAller, and others. Low Tidal Volume Ventilation Is Associated with Reduced Mortality in HIV-infected Patients with Acute Lung Injury. Thorax. June 5, 2008 [Epub ahead of print].

Related Articles

PD Walzer, HE Evans, AJ Copas, and others. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clinical Infectious Diseases 46(4): 625-633. February 15, 2008.

MO Meade, DJ Cook, GH Guyatt, and others (Lung Open Ventillation Study). Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 299(6): 637-645. February 13, 2008.

M Yilmaz, MT Keegan, R Iscimen, and others. Toward the prevention of acute lung injury: protocol-guided limitation of large tidal volume ventilation and inappropriate transfusion. Critical Care Medicine 35(7): 1660-1666; quiz 1667. July 2007.

N Petrrucci and W Iacovelli. Lung protective ventilation strategy for the acute respiratory distress syndrome. Cochrane Database Systemic Review (3): CD003844. July 18, 2007.

NJ Umoh, E Fan, PA Mendez-Tellez, and others. Patient and intensive care unit organizational factors associated with low tidal volume ventilation in acute lung injury. Critical Care Medicine 36(5): 1463-1468. May 2008.

 

 

 

 

 

 

 

 

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritonavir)
Lexiva (fosamprenavir)
Norvir (ritonavir)
Prezista (darunavir)
Reyataz (atazanavir)
Viracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (zidovudine/lamivudine)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (tenofovir / emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
Etravirine (Intelence; TMC125)
Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry ( maraviroc)
Fixed-dose Combinations
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir (zidovudine + lamivudine)
Trizivir (abacavir + zidovudine + lamivudine)
Truvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)